BMO Capital on SAGE Therapeutics (SAGE): 'Another Important Milestone Achieved with Brexanolone Filing for PPD'
Tweet Send to a Friend
BMO Capital maintains Outperform on Sage Therapeutics (NASDAQ: SAGE) price target of $203.00.Analyst Gary Nachman comments "SAGE announced the NDA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
